Cargando…

Safety and Impact of Anti-COVID-19 Vaccines in Psoriatic Patients Treated with Biologics: A Real Life Experience

Since all clinical trials conducted during the development of anti-COVID-19 vaccines have adopted among the exclusion criteria the presence of immunodepression or immunomodulating therapy, to date, the effects of vaccination against the new coronavirus 2 in people under such conditions have yet to b...

Descripción completa

Detalles Bibliográficos
Autores principales: Skroza, Nevena, Bernardini, Nicoletta, Tolino, Ersilia, Proietti, Ilaria, Mambrin, Alessandra, Marchesiello, Anna, Marraffa, Federica, Rossi, Giovanni, Volpe, Salvatore, Potenza, Concetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8347527/
https://www.ncbi.nlm.nih.gov/pubmed/34362136
http://dx.doi.org/10.3390/jcm10153355
_version_ 1783735111196344320
author Skroza, Nevena
Bernardini, Nicoletta
Tolino, Ersilia
Proietti, Ilaria
Mambrin, Alessandra
Marchesiello, Anna
Marraffa, Federica
Rossi, Giovanni
Volpe, Salvatore
Potenza, Concetta
author_facet Skroza, Nevena
Bernardini, Nicoletta
Tolino, Ersilia
Proietti, Ilaria
Mambrin, Alessandra
Marchesiello, Anna
Marraffa, Federica
Rossi, Giovanni
Volpe, Salvatore
Potenza, Concetta
author_sort Skroza, Nevena
collection PubMed
description Since all clinical trials conducted during the development of anti-COVID-19 vaccines have adopted among the exclusion criteria the presence of immunodepression or immunomodulating therapy, to date, the effects of vaccination against the new coronavirus 2 in people under such conditions have yet to be clearly defined. The primary objective of the study is to assess the safety of treatment with biotechnological drugs in patients suffering from moderate–severe psoriasis and subjected to the prophylactic vaccination against SARS-Cov-2. Additionally, the secondary objective of the research is to investigate the existence of a possible impact of anti-COVID-19 vaccination on the natural chronic-relapsing course and the severity of the psoriatic disease. The study included 436 patients with moderate–severe psoriasis, both male and female, in treatment with biologics. The data were collected using the direct interview method. A reduction of 74.13% of average Psoriasis Area Severity Index (PASI )compared to baseline (T0) was found in all subjects; this does not differ significantly from the group that underwent vaccination (73.4%). Moreover; at the end of the study, neither mild nor severe adverse events (ADR) were observed among them. In conclusion, biotechnological drugs used in the management of patients with moderate–severe psoriasis demonstrate a high safety profile also in subjects immunized against SARS-Cov-2.
format Online
Article
Text
id pubmed-8347527
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83475272021-08-08 Safety and Impact of Anti-COVID-19 Vaccines in Psoriatic Patients Treated with Biologics: A Real Life Experience Skroza, Nevena Bernardini, Nicoletta Tolino, Ersilia Proietti, Ilaria Mambrin, Alessandra Marchesiello, Anna Marraffa, Federica Rossi, Giovanni Volpe, Salvatore Potenza, Concetta J Clin Med Article Since all clinical trials conducted during the development of anti-COVID-19 vaccines have adopted among the exclusion criteria the presence of immunodepression or immunomodulating therapy, to date, the effects of vaccination against the new coronavirus 2 in people under such conditions have yet to be clearly defined. The primary objective of the study is to assess the safety of treatment with biotechnological drugs in patients suffering from moderate–severe psoriasis and subjected to the prophylactic vaccination against SARS-Cov-2. Additionally, the secondary objective of the research is to investigate the existence of a possible impact of anti-COVID-19 vaccination on the natural chronic-relapsing course and the severity of the psoriatic disease. The study included 436 patients with moderate–severe psoriasis, both male and female, in treatment with biologics. The data were collected using the direct interview method. A reduction of 74.13% of average Psoriasis Area Severity Index (PASI )compared to baseline (T0) was found in all subjects; this does not differ significantly from the group that underwent vaccination (73.4%). Moreover; at the end of the study, neither mild nor severe adverse events (ADR) were observed among them. In conclusion, biotechnological drugs used in the management of patients with moderate–severe psoriasis demonstrate a high safety profile also in subjects immunized against SARS-Cov-2. MDPI 2021-07-29 /pmc/articles/PMC8347527/ /pubmed/34362136 http://dx.doi.org/10.3390/jcm10153355 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Skroza, Nevena
Bernardini, Nicoletta
Tolino, Ersilia
Proietti, Ilaria
Mambrin, Alessandra
Marchesiello, Anna
Marraffa, Federica
Rossi, Giovanni
Volpe, Salvatore
Potenza, Concetta
Safety and Impact of Anti-COVID-19 Vaccines in Psoriatic Patients Treated with Biologics: A Real Life Experience
title Safety and Impact of Anti-COVID-19 Vaccines in Psoriatic Patients Treated with Biologics: A Real Life Experience
title_full Safety and Impact of Anti-COVID-19 Vaccines in Psoriatic Patients Treated with Biologics: A Real Life Experience
title_fullStr Safety and Impact of Anti-COVID-19 Vaccines in Psoriatic Patients Treated with Biologics: A Real Life Experience
title_full_unstemmed Safety and Impact of Anti-COVID-19 Vaccines in Psoriatic Patients Treated with Biologics: A Real Life Experience
title_short Safety and Impact of Anti-COVID-19 Vaccines in Psoriatic Patients Treated with Biologics: A Real Life Experience
title_sort safety and impact of anti-covid-19 vaccines in psoriatic patients treated with biologics: a real life experience
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8347527/
https://www.ncbi.nlm.nih.gov/pubmed/34362136
http://dx.doi.org/10.3390/jcm10153355
work_keys_str_mv AT skrozanevena safetyandimpactofanticovid19vaccinesinpsoriaticpatientstreatedwithbiologicsareallifeexperience
AT bernardininicoletta safetyandimpactofanticovid19vaccinesinpsoriaticpatientstreatedwithbiologicsareallifeexperience
AT tolinoersilia safetyandimpactofanticovid19vaccinesinpsoriaticpatientstreatedwithbiologicsareallifeexperience
AT proiettiilaria safetyandimpactofanticovid19vaccinesinpsoriaticpatientstreatedwithbiologicsareallifeexperience
AT mambrinalessandra safetyandimpactofanticovid19vaccinesinpsoriaticpatientstreatedwithbiologicsareallifeexperience
AT marchesielloanna safetyandimpactofanticovid19vaccinesinpsoriaticpatientstreatedwithbiologicsareallifeexperience
AT marraffafederica safetyandimpactofanticovid19vaccinesinpsoriaticpatientstreatedwithbiologicsareallifeexperience
AT rossigiovanni safetyandimpactofanticovid19vaccinesinpsoriaticpatientstreatedwithbiologicsareallifeexperience
AT volpesalvatore safetyandimpactofanticovid19vaccinesinpsoriaticpatientstreatedwithbiologicsareallifeexperience
AT potenzaconcetta safetyandimpactofanticovid19vaccinesinpsoriaticpatientstreatedwithbiologicsareallifeexperience